Evidence map›Paper›PMID 36139129›Full record

ArticleBiomolecules2022

The Protective Effect of Simvastatin on the Systolic Function of the Heart in the Model of Acute Ischemia and Reperfusion Is Due to Inhibition of the RhoA Pathway and Independent of Reduction of MMP-2 Activity.

Monika Skrzypiec-Spring, Agnieszka Sapa-Wojciechowska, Alina Rak-Pasikowska, Maciej Kaczorowski, Iwona Bil-Lula, Agnieszka Hałoń, Adam Szeląg

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Monika Skrzypiec-SpringDepartment of Pharmacology, Wrocław Medical University, 50-345 Wrocław, Poland.ORCID 0000-0003-1641-8025
Agnieszka Sapa-WojciechowskaDepartment of Clinical Chemistry, Wrocław Medical University, 50-556 Wrocław, Poland.
Alina Rak-PasikowskaDepartment of Clinical Chemistry, Wrocław Medical University, 50-556 Wrocław, Poland.
Maciej KaczorowskiDepartment of Clinical and Experimental Pathology, Wrocław Medical University, 50-556 Wrocław, Poland.ORCID 0000-0002-7787-9952
Iwona Bil-LulaDepartment of Clinical Chemistry, Wrocław Medical University, 50-556 Wrocław, Poland.
Agnieszka HałońDepartment of Clinical and Experimental Pathology, Wrocław Medical University, 50-556 Wrocław, Poland.
Adam SzelągDepartment of Pharmacology, Wrocław Medical University, 50-345 Wrocław, Poland.
Wroclaw Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study investigated whether Rho-associated protein kinase (RhoA/ROCK) signaling pathway inhibitor simvastatin inhibits matrix metalloproteinase 2 (MMP-2) activity in a rat ischemia-reperfusion injury (I/Ri) model by inhibiting the RhoA/ROCK pathway and reducing

Indexed as

Matrix Metalloproteinase 2Reperfusion Injuryrho-Associated KinasesSimvastatinAnimalsMyosin Light ChainsRatsRats, Sprague-Dawleyrho GTP-Binding ProteinsRNA, MessengerTroponin IMatrix Metalloproteinase 2Myosin Light ChainsRhoA protein, ratrho-Associated Kinasesrho GTP-Binding ProteinsRNA, MessengerSimvastatinTroponin Iischemia/reperfusionmatrix metalloproteinasesRhoAsimvastatin

Identifiers

PMID36139129
PMCPMC9496379
OpenAlexW4296747664

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.